NCT00509002View on ClinicalTrials.gov

Iressa Study in Patients With Salivary Gland Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Salivary Gland Cancer

Interventions

DRUG

Gefitinib

250 mg by mouth once a day, every day, at about same time in morning.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER